"Sulfonamides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of compounds that contain the structure SO2NH2.
| Descriptor ID |
D013449
|
| MeSH Number(s) |
D02.065.884 D02.886.590.700
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Sulfonamides".
Below are MeSH descriptors whose meaning is more specific than "Sulfonamides".
This graph shows the total number of publications written about "Sulfonamides" by people in this website by year, and whether "Sulfonamides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 1 | 0 | 1 |
| 1995 | 1 | 0 | 1 |
| 1996 | 2 | 0 | 2 |
| 1997 | 1 | 1 | 2 |
| 2000 | 4 | 2 | 6 |
| 2001 | 0 | 1 | 1 |
| 2002 | 4 | 0 | 4 |
| 2003 | 7 | 3 | 10 |
| 2004 | 2 | 3 | 5 |
| 2005 | 3 | 5 | 8 |
| 2006 | 6 | 6 | 12 |
| 2007 | 8 | 2 | 10 |
| 2008 | 9 | 3 | 12 |
| 2009 | 3 | 4 | 7 |
| 2010 | 3 | 4 | 7 |
| 2011 | 6 | 6 | 12 |
| 2012 | 10 | 2 | 12 |
| 2013 | 8 | 3 | 11 |
| 2014 | 9 | 7 | 16 |
| 2015 | 1 | 4 | 5 |
| 2016 | 3 | 4 | 7 |
| 2017 | 4 | 1 | 5 |
| 2018 | 2 | 2 | 4 |
| 2019 | 8 | 1 | 9 |
| 2020 | 4 | 4 | 8 |
| 2021 | 5 | 7 | 12 |
| 2022 | 0 | 5 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sulfonamides" by people in Profiles.
-
A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes. Am J Hematol. 2023 02; 98(2):272-281.
-
Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2022 11; 6:e2200191.
-
Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Na?ve Acute Myeloid Leukemia. Clin Cancer Res. 2022 07 01; 28(13):2744-2752.
-
Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AML. In Vivo. 2022 Jul-Aug; 36(4):1615-1627.
-
Endothelin-axis antagonism enhances tumor perfusion in pancreatic cancer. Cancer Lett. 2022 09 28; 544:215801.
-
Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study. J Immunother Cancer. 2022 03; 10(3).
-
Measurable Residual Disease Response and Prognosis in Treatment-Na?ve Acute Myeloid Leukemia With Venetoclax and Azacitidine. J Clin Oncol. 2022 03 10; 40(8):855-865.
-
The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma. Nat Commun. 2021 11 09; 12(1):6468.
-
Leptomeningeal Dissemination of Low-Grade Neuroepithelial Tumor with FGFR1_TACC1 Fusion with Clinical and Radiographic Response to Pazopanib and Topotecan. Pediatr Neurosurg. 2022; 57(1):63-68.
-
Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase 1b study (GO28440). Haematologica. 2021 11 01; 106(11):2834-2844.